
Teva Pharmaceutical (TEVA) Stock Forecast & Price Target
Teva Pharmaceutical (TEVA) Analyst Ratings
Bulls say
Teva Pharmaceutical Industries demonstrates a solid growth trajectory, evidenced by projected sales increases for key products such as Ajovy and Uzedy, with forecasts of $785 million and $278 million respectively by 2026, reflecting respective year-over-year growth rates of 17% and 45%. The company's successful strategic focus on higher-value products is expected to enhance EBITDA margins, with a strong anticipated cash flow expansion by 2027, bolstered by substantial cost savings of $700 million. With significant market share opportunities in high-demand therapeutic areas and ongoing sales growth in established products like Austedo, Teva is poised for continued financial resilience and growth in the coming years.
Bears say
Teva Pharmaceutical Industries faces a challenging financial outlook due to expected sequential declines in Q1 2026 sales resulting from inventory patterns and a Year-over-Year decrease anticipated in Q4 2026 due to pricing pressures leading up to Inflation Reduction Act (IRA) implementation. Additionally, while Austedo sales are projected to rise in 2026, a downturn is expected in 2027, reflecting potential volatility in their revenue streams, especially within their generics division, which reported revenues that missed estimates by 3% due to a significant Year-over-Year decline in US prescriptions. Furthermore, regulatory uncertainties surrounding tariffs and Most-Favored-Nation policies, along with challenges in litigation and pipeline execution, pose additional risks that could hinder Teva's financial recovery and operational stability.
This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Teva Pharmaceutical (TEVA) Analyst Forecast & Price Prediction
Start investing in Teva Pharmaceutical (TEVA)
Order type
Buy in
Order amount
Est. shares
0 shares